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TObjective: The diversity of biologic valves available to replace the aortic valve
renders selection difficult for the 45- to 65-year-old patient. To evaluate and
compare the results of biologic valves in the 45- to 65-year-old patient, we reviewed
our experience (1991-2004).
Methods: Three hundred thirty-two patients between 45 and 65 years old with
isolated aortic valve disease had a biologic valve implanted: Freestyle valve in 140
patients, a homograft in 54 patients, a stented Mosaic or Perimount valve (stented
xenograft) in 62 patients, and a Ross procedure in 76 patients.
Results: Perioperative mortality was comparable for all groups (Freestyle, 2.1%;
homograft, 3.7%; stented xenograft, 3.2%; Ross procedure, 1.3%; P  .8). Echo-
cardiographically determined valve performance at discharge was significantly
enhanced in the Ross procedure and homograft groups (indexed effective orifice
area: Freestyle, 0.9  0.3 cm2/m2; homograft, 1.3  0.3 cm2/m2; stented xenograft,
0.8  0.2 cm2/m2; Ross procedure, 1.4  0.4; P  .0001; mean gradient: Freestyle,
12.0 6.6 mm Hg; homograft, 7.4 4.0 mm Hg; stented xenograft, 15.4 5.4 mm
Hg; Ross procedure, 4.6  3.2 mm Hg; P  .0001). For all yearly follow-up,
freedom from New York Heart Association class III or IV was comparable and
greater than 95% for all groups. At 7 years, cardiac survival (homograft, 96.3% 
3.7%; Ross procedure, 90.6%  6.3%; stented xenograft, 86.0%  10.3%; Free-
style, 89.2%  10.8%; P  .7) and freedom from reoperation (Ross procedure,
98.5%  1.4%; homograft, 90.6%  5.7%; Freestyle, 88.0%  4.9%; stented
xenograft, 90.0%  8.0%; P  .4) were comparable. Freedoms from significant
bleeding events, valve-related neurologic events, or endocarditis were comparable
and greater than 95% for all groups.
Conclusion: Type of aortic biologic valve for the 45- to 65-year-old patient does not
affect midterm survival or valve-related morbidity. Thus the choice of biologic
valve for the 45- to 65-year-old patient should be dictated by patient-surgeon
preference, ease of implantation, and reoperation until longer comparative studies
are available.
The incidence of aortic valve replacement is increasing, mainly because ofpopulation aging. Moreover, congenital aortic valve disease remains acommon indication for aortic valve replacement in the current era of
cardiac surgery. Selection of valve type for aortic valve replacement depends on
many factors, such as the patient’s age, life expectancy, valve durability, and
anticoagulation-related issues. Within the pediatric age group, the Ross proce-
dure has gained popularity, especially because of the autograft’s capacity to
enlarge with patient growth.1 Excellent durability and hemodynamic perfor-
mance with acceptable valve-related morbidity have been reported for pediatric
patients undergoing a Ross procedure.2,3 On the other hand, mechanical valves,
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CDeither unileaflet tilting discs or bileaflet discs, show ex-
cellent durability in the young and middle-aged popula-
tion.4,5 However, mechanical valve replacement exposes
the patient to the cumulative risks of lifelong anticoagu-
lation. On the contrary, biologic aortic valve substitutes
have traditionally been shown to be more prone to struc-
tural valve deterioration in the younger age groups.6,7
However, the excellent long-term outcomes reported with
biologic valves in patients older than 65 years coupled
with the lower operative mortality for reoperative pros-
thetic aortic valve failure increase interest in comparing
outcomes of current biologic valves in the middle-aged
adult. The present report aims to compare midterm out-
comes of currently available biologic aortic valve substi-
tutes (aortic homograft, Ross procedure, stentless xeno-
graft, and stented xenograft) for 45- to 65-year-old
patients requiring aortic valve replacement.
Methods
Patient Population
Between September 1991 and April 2004, 332 patients aged be-
tween 45 and 65 years underwent a biologic aortic valve replace-
ment at the Québec Heart Institute: a Ross procedure in 76 pa-
TABLE 1. Patient characteristics (n  332)
Freestyle
(n  140)
Homograft
(n  54)
Age (y) 59.0  5.1 53.5  5.9
Sex (% male) 57.9 63.0
Diabetes (%) 15.7 7.4
BMI 30 (%) 28.6 24.1
CVA (%) 5.0 9.3
Vascular disease (%) 4.3 16.7
HBP (%) 40.0 40.7
Current smoker (%) 14.0 17.3
COPD (%) 17.1 9.4
AF (%) 5.7 7.4
Parsonnet score (mean) 8.1  6.5 9.0  7.3
BMI, Body mass index; CVA, cerebrovascular accident; HBP, high blood
TABLE 2. Perioperative data (n  332)
Freestyle
(n  140)
Homograf
(n  54)
CPB time (min) 122.6  32.5 124.2  33
Crossclamp time (min) 94.7  22.8 93.3  25
Prolonged intubation (%) 2.1 5.6
Renal failure (%) 4.3 0.0
Mediastinitis (%) 0.0 0.0
Septicemia (%) 0.7 0.0
Length of stay (d) 8.4  4.5 8.9  8
Observed mortality (%) 2.1 3.7CPB, Cardiopulmonary bypass.
1042 The Journal of Thoracic and Cardiovascular Surgery ● Matients, a Freestyle valve in 140 patients, a stented xenograft in 62
patients, and an aortic homograft in 54 patients. During the same
period, 3336 patients underwent aortic valve replacement in our
institution. Decisions to implant a biologic valve at a younger age,
as well as the type of biologic valve selected, were left to surgeon-
patient preference. During the same time interval, 257 mechanical
aortic valves were implanted in patients aged 45 to 65 years. No
patient had significant coronary artery disease requiring coronary
artery bypass grafting to limit the effect of ischemic disease on
outcome. Patient characteristics are listed in Table 1. Mean age at
valve implantation was significantly lower in the homograft and
Ross groups. A trend toward a lower comorbid profile was ob-
served in the Ross group, as suggested by a lower mean Parsonnet
score.
Valve Substitute and Surgical Technique
All homografts were harvested locally within 24 hours after donor
death. Valves were subsequently shipped to Cryolife Inc (Marietta,
Ga) and cryopreserved according to the company’s protocol on the
basis of liquid nitrogen freezing in an antibiotic and dimethyl
sulfoxide solution. Homografts were used in a root configuration in
85.2% of patients and with a scalloped subcoronary implantation
technique in 14.8% of patients. Selection of the size of the pul-
monary homograft for the Ross procedure was based on the largest
Mosaic  Perimount
(n  62)
Ross
(n  76) P value
61.0  4.0 51.1  3.6 .0001
67.7 56.6 .50
17.7 6.6 .09
33.9 29.3 .71
8.1 2.6 .34
8.2 6.6 .03
41.9 27.6 .23
21.3 24.0 .29
17.7 7.9 .16
0.0 1.3 .08
10.1  9.5 6.6  6.5 .12
ure; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation.
Mosaic  Perimount
(n  62)
Ross
(n  76) P value
90.0  32.1 146.0  33.7 .0001
66.9  25.2 112.9  25.9 .0001
9.7 0.0 .01
4.8 4.0 .48
1.6 0.0 .23
1.6 2.7 .50
8.0  5.1 8.0  4.4 .79
3.2 1.3 .80t
.8
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significant anomaly of the pulmonic valve is considered a contra-
indication to proceed with the Ross procedure in our institution.
Freestyle (Medtronic Inc, Minneapolis, Minn) valves were im-
planted mainly by using a freehand subcoronary technique
(78.6%). The noncoronary sinus was not scalloped in the majority
of patients with the subcoronary technique. A root configuration
was used in 21.4% of cases, mainly in patients with aortic root
disease. Stented xenografts used were either the Mosaic valve in
66% of cases (Medtronic) or the Perimount valve in 34% of cases
(Edwards, Irvine, Calif). All operations were conducted during
cardiopulmonary bypass with moderate hypothermia. Although
implantation techniques were standard among surgeons, myocar-
dial preservation techniques varied among surgeons.
Follow-up and Statistics
All surviving patients were assessed by means of echocardiogra-
phy before hospital discharge. Follow-up was 100% complete.
Mean follow-up was 4.7  2.9 years for the whole cohort, 5.4 
2.9 for the Freestyle group, 4.0  2.3 for the homograft group, 2.7
 2.1 for the stented xenograft group, and 5.6  3.1 for the Ross
group. Patients were followed at the Laval Hospital Cardiac Sur-
gery Valve Clinic. Every other year, all patients had a clinical
evaluation by the operating surgeon and underwent echocardiog-
raphy. In years without clinical visits, the patient was contacted by
telephone and evaluated by the same clinical research nurse ac-
cording to a standard questionnaire. All hospitalization records
were prospectively collected during the follow-up period. Valve-
related morbidity and mortality were recorded according to previ-
ously published guidelines and collected prospectively.8 All deaths
were thoroughly investigated through hospitalization records or
autopsy reports. Cardiac-related mortality was defined as all valve-
related and unrelated cardiac events, including unexplained deaths.
The Journal of ThoracicResults of quantitative and nominal variables were expressed as
means  SD and percentages, respectively. One-way analysis of
variance was performed to carry out analyses for comparisons
between groups. The normality assumption was verified with the
Shapiro-Wilk test. The Brown and Forsythe variation and the
Levene test were used to verify the homogeneity of variances.
When these assumptions were not fulfilled, an alternative proce-
dure independent of these assumptions was done. The procedure
performed was to replace the observations by their rank (ie, rank
transformation) and to apply the ordinary F test from 1-way
analysis of variance. This technique is an approximate procedure,
but one that has good statistical properties when compared with the
Kruskal-Wallis test. Posteriori comparisons were performed by
using the Tukey technique. Categoric variables were analyzed with
Fisher exact tests. Product-limit analyses (also called Kaplan-
Meier analyses) were performed to examine the time-dependent
cumulative probabilities of the outcomes. The plots of the negative
log of the survival function versus time revealed that exponential
models were not appropriate for the survival data. Consequently,
the log rank tests with associated 2 tests were used to test the
hypothesis that there was no difference in survival functions be-
tween both groups. The data were analyzed with the statistical
package program SAS (SAS Institute Inc., Cary, NC).
Results
Perioperative Data
Perioperative data are shown in Table 2. Aortic crossclamp and
cardiopulmonary bypass times were significantly lower in the
stented xenograft group. Perioperative morbidity was low and
comparable for all groups other than a significantly higher
incidence of prolonged intubation in the stented xenograft
Figure 1. Freedom from all death.group. The hospital mortality was slightly higher, albeit non-
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CD significant, in the stented xenograft and homograft groups. Atdischarge, transthoracic echocardiography showed a signifi-
cantly enhanced valve performance in the homograft and Ross
groups compared with the Freestyle and stented xenograft
groups (indexed effective valve orifice area: Freestyle, 0.9 
0.3 cm2/m2; homograft, 1.3  0.3 cm2/m2; stented xenograft,
0.8  0.2 cm2/m2; Ross procedure, 1.4  0.4 cm2/m2; P 
.0001, mean gradient: Freestyle, 12.0  6.6 mm Hg; ho-
mograft, 7.4 4.0 mm Hg; stented xenograft, 15.4 5.4 mm
Hg; Ross procedure, 4.6  3.2 mm Hg; P  .0001).1044 The Journal of Thoracic and Cardiovascular Surgery ● MaSurvival and Valve-Related Morbidity
Data on survival and valve-related morbidity are shown in
Figures 1 through 3. At 7 years, a lower actuarial overall
survival was observed in the Freestyle and stented xenograft
groups compared with that in the Ross group, although this
difference was nonsignificant (Freestyle, 79.8%  4.3%;
homograft, 83.9%  6.2%; stented xenograft, 76.4% 
11.0%; Ross procedure, 91.8%  4.4%; stented xenograft
vs Ross procedure, P  .14; Freestyle vs Ross procedure, P
 .26; Figure 1).
Figure 2. Freedom from cardiac death.
Figure 3. Freedom from reoperation.y 2005
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were of noncardiac cause; of these, 11 were encountered in
the Freestyle group. When assessing cardiac survival, actu-
arial survival curves were similar for all groups at 7 years
(homograft, 96.3%  3.7%; Ross procedure, 90.6% 
6.3%; stented xenograft, 86.0%  10.3%; Freestyle, 89.2%
 10.8%; P .7; Figure 2). Among the 14 cardiac deaths,
5 were valve related (Freestyle, 2; Ross procedure, 2;
stented xenograft, 1; homograft, 0; P  not significant), 1
death in the Freestyle group remained unexplained, and 8
cardiac deaths were not valve related (Freestyle, 3; ho-
mograft 2; stented xenograft, 2; Ross procedure, 1; P  not
significant). Freedom from valve endocarditis (Freestyle,
97.4%  2.0%; homograft, 97.7%  2.2%; stented xeno-
graft, 98.3%  1.7%; Ross procedure, 100%  0%; P 
.6), valve-related thromboembolism (Freestyle, 97.7% 
1.3%; homograft, 100%  0%; stented xenograft, 100% 
0%; Ross procedure, 100%  0%; P  .3), severe bleeding
(Freestyle, 95.4%  2.0%; homograft, 96.0%  2.8%;
stented xenograft, 98.3% 1.7%; Ross procedure, 100%
0%; P  .4), and hemolysis (Freestyle, 100%  0%;
homograft, 100%  0%; stented xenograft, 100%  0%;
Ross procedure, 100%  0%) were comparable at 7 years
for all groups.
Figure 3 demonstrates a similar incidence of reoperation
(Ross procedure, 98.5%  1.4%; homograft, 90.6% 
5.7%; Freestyle, 88.0%  4.9%; stented xenograft, 90.0%
 8.0%; P  .4) for all study groups at 7 years. No patient
undergoing the Ross procedure required reoperation for
pulmonary homograft stenosis. When assessing combined
freedom from all valve-related morbidity and cardiac mor-
tality, differences were observed among groups (Freestyle,
66.1%, homograft, 83.9%; stented xenograft, 77.8%; Ross
procedure, 86.0%), although they were not significant at 7
years (Ross procedure vs stented xenograft, P  .14; Ross
procedure vs Freestyle, P  .26; Ross procedure vs ho-
mograft, P  .28).
Functional Class Assessment and Valve Performance
For all yearly follow-up, freedom from functional class III
and IV was greater than 95% and comparable for all groups.
At 6 months postoperatively, the indexed effective valve
orifice area had increased in all groups (Freestyle, 1.0 0.3
cm2/m2; homograft, 1.4  0.3 cm2/m2; stented xenograft,
0.9  0.2 cm2/m2; Ross procedure, 1.5  0.4 cm2/m2) but
remained significantly higher in the Ross procedure and
homograft groups compared with the Freestyle or stented
xenograft groups (P  .0001). Similarly, mean transvalvu-
lar gradients decreased in all groups and continued to be
significantly lower in the Ross procedure and homograft
groups (Freestyle, 8.6  5.2 mm Hg; homograft, 4.4  3.3
mm Hg; stented xenograft, 13.0  6.3 mm Hg; Ross pro-
cedure, 3.0  2.7 cm2/m2; P  .0001). Subsequently, he-
The Journal of Thoracicmodynamic performance remained stable throughout the
study period for all groups. Only 3 patients showed signif-
icant aortic regurgitation at follow-up ( class III-IV/IV).
One patient in the Freestyle group required reoperation 5.5
years after the initial implantation, 1 patient in the stented
xenograft group experienced an early prosthetic endocardi-
tis necessitating reoperation, and 1 patient in the Ross
procedure group is currently being followed for ongoing
class III-IV autograft regurgitation 10 years postoperatively.
Discussion
The ideal biologic valve should show good hemodynamic
characteristics, be easy to implant, and demonstrate excel-
lent durability with minimal valve-related complications.
Reports assessing the long-term outcomes of stented por-
cine or bovine pericardial valves for patients older than 65
years show excellent valve durability with low valve-related
complications.9,10 On the other hand, durability of biologic
valves in younger patients has been reported to be inversely
related to age at implantation.11 Comparison of outcomes
for currently available biologic valves in middle-aged pa-
tients (45-65 years) requiring aortic valve replacement re-
main sparse. The present study, from a single high-volume
center, reports results comparing midterm outcomes of cur-
rently available biologic valves for the 45- to 65-year-old
patient choosing a biologic prosthesis for aortic valve re-
placement. Results show comparable cardiac-related sur-
vival. Valve-related morbidity, including structural valve
dysfunction, was low for all valve types. Although hemo-
dynamic performance was enhanced in patients with a Ross
or homograft procedure, freedom from functional class III
or IV on follow-up was high and comparable for all groups.
Because of their excellent durability, mechanical valves
have been the mainstay of aortic valve replacement for
young and middle-aged patients.12,13 However, thromboem-
bolic complications, anticoagulation-related complications,
tissue pannus ingrowth, and endocarditis plague the long-
term outcome of mechanical valves. Furthermore, studies
have shown comparable long-term survival between me-
chanical and bioprosthetic aortic valves.14 Unileaflet tilting
disc valves have been supplanted by their bileaflet counter-
parts. Complication rates among current bileaflet disc
valves are similar.15,16 In an attempt to decrease thrombo-
genicity, new prosthesis designs, such as the pure carbon
On-X valve, have failed to decrease the incidence of throm-
boembolic events in at least one study.17 Moreover, bleed-
ing events related to lifelong anticoagulation with mechan-
ical valves remain a significant source of morbidity.
Bleeding complications are increased in elderly patients,
and higher levels of international normalized ratio (INR) are
seen.18,19 Reports assessing ranges of INR have shown up to
40% of INR levels to be out of the recommended range.20
and Cardiovascular Surgery ● Volume 129, Number 5 1045
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ate use of coumadin-based anticoagulation. Although dura-
bility remains the main limitation to implantation of bio-
logic valves in younger patients, the current midterm report
did not delineate significant differences among currently
available biologic valves for the 45- to 65-year old age
group. In addition to valve durability and valve-related
complications, other patient- and valve-related variables,
such as patient comorbidities and valvular cause, ease of
implantation and reoperation, and prosthesis characteristics
and availability, have to be taken into account when eval-
uating the type of biologic valve to implant in a middle-aged
patient. Patients requiring aortic valve replacement at a
younger age show decreased long-term survival compared
with a matched undiseased population, mainly because of
the presence of comorbidities, such as concomitant coro-
nary artery disease or cardiomyopathy.21 Such comorbidi-
ties are important considerations in the decision-making
process to implant a biologic valve at a younger age.
Considering differences in the risk profile between
groups, the present study shows similar perioperative mor-
tality and morbidity for the 4 types of biologic valves,
although the level of implantation complexity differs among
the valve types, as suggested by the increased cardiopulmo-
nary bypass and crossclamp times in the homograft, Free-
style, and Ross procedure groups. Excellent perioperative
results have also been reported by other high-volume cen-
ters dedicated to complex root-reconstruction proce-
dures.22,23 However, stentless valves, the Ross procedure,
and allograft implantation are known to be associated with
a significant number of technical pitfalls that might affect
early outcome.24
Considering the high probability of reoperation when
implanting biologic valves in younger patients, risks of
reoperation according to valve type must be evaluated. With
increasing experience and enhanced myocardial preserva-
tion techniques, mortality for reoperative aortic valve re-
placement has been reported to be as low as 1.2% for
stented xenografts.21 On the other hand, root reintervention
in a calcified homograft remains a challenging operation
that might incur significant complications. Although not
encountered in the present study, immunologic mediated
pulmonary homograft stenosis or autograft failure caused by
root dilatation have been reported as a significant cause of
failure after the Ross procedure.25,26 In a study comprising
a limited number of patients, Lucian and colleagues27 have
reported a significantly higher mortality for reoperative op-
erations of stentless valves compared with stented biopros-
theses.
Valve performance was significantly enhanced in the
homograft and Ross procedure groups. However, the
effect of valve performance on patient survival or func-
tional status is highly debated.28,29 Within the present
1046 The Journal of Thoracic and Cardiovascular Surgery ● Mastudy, no significant advantage on functional class out-
come was observed with the homograft or Ross proce-
dure. However, recent studies have demonstrated the
importance of avoiding severe mismatch in patients un-
dergoing aortic valve replacement, especially in the pres-
ence of left ventricular dysfunction.30,31 Although a rare
clinical setting, when encountering a small aortic root
with a potential to induce a severe mismatch, selection of
a biologic valve with a better hemodynamic profile or
performance of a root-enlargement procedure should be
considered. Selection of the type of biologic valve might
also be influenced by valve pathology. Homografts, be-
cause of their low risk of reinfection and flexibility in
implantation technique, comprise an excellent conduit in
the presence of active endocarditis. However, homograft
availability remains sparse, and valve durability might be
influenced by delay in graft procurement, donor age, graft
quality, and host immunologic response.32,33
Although this study represents one of few reports
comparing biologic aortic valves in the middle-aged pa-
tient, study limitations should be addressed. The present
study is limited to midterm results, and longer follow-up
will possibly allow better delineation of the rate of valve
failure, as well as the mode of such failures. Future
studies assessing the benefits of biologic valves in young
patients will have to take into account the risks of reop-
eration compared with the risks of long-term anticoagu-
lation. Recently, Gaudiani and associates,34 using a risk
model, showed the risks of reoperation with biologic
valves to be comparable with the long-term risks of
anticoagulation. Furthermore, development of self-
management INR-monitoring strategies might result in a
decrease in anticoagulation-mediated morbidity and limit
the benefits of use of biologic valves in younger pa-
tients.35,36 Similarly, the burden of anticoagulation-
mediated morbidity in patients with mechanical valves
might also be decreased through investigation of new
anticoagulant agents, such as ximelagatran, a direct
thrombin inhibitor.37 On the other hand, development in
the field of biologic valves, such as tissue heart valve
engineering, might offer new strategies to increase valve
durability.38
In conclusion, current available biologic valves show
comparable outcomes at midterm for the 45- to 65-year-old
patient choosing a biologic valve for aortic valve replace-
ment. Until long-term comparative studies are available,
selection of a biologic valve for the 45- to 65-year-old
patient should also take into account patient characteristics
and comorbidities, ease of valve implantation and reopera-
tion, and surgical expertise. Developments in tissue valve
engineering and anticoagulation regimens will probably af-
fect the decision-making process in terms of valve selection
y 2005
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CDfor the middle-aged patient requiring aortic valve replace-
ment in the near future.
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Discussion
Dr W. R. Eric Jamieson (Vancouver, British Columbia, Canada).
Dr Dagenais, I congratulate you on a very excellent topic. This is
a difficult group of patients, and the decision of which valve to
implant is a difficult one. There are obviously certain limitations to
the study because of the numbers and complexity of the various
procedures, but I think it is extremely important that we discuss
this. I have about 7 short questions related to this particular topic.
It appears that your longest experience comes with the Ross
and the Freestyle, of which you were part of the regulatory trial,
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CDand our beloved colleague, Dr Cratier, who died untimely, did a lot
of these Ross procedures. Do you believe that there has been a
change in your pattern of practice toward the homograft and the
stented xenograft, and if so, for what reason?
Dr Dagenais. Yes, we had changes in terms that we possibly
do less Ross procedures in the 45- to 65-year-old patient, and now
we use more stented xenografts. We decided to do this study
because we had no true decision making in these patients.
Dr Jamieson. My other questions relate to the homograft. You
did 85% roots, and in the Freestyle group your roots were 21%. As
to the homograft experience, were there a lot of cases of endocar-
ditis while you were using the root?
Dr Dagenais. I think there were only 3 cases of endocarditis in
this study, and that is why we included them.
Dr Jamieson. Do you have concern about the future with
regard to root homografts? You know all these patients potentially
are going to get a second operation and maybe a third in their
lifetimes, but the calcification of the homograft root and the
potential with the root replacement in the Freestyle, amino oleic
acid being very effective on the leaflets but not quite as effective
on the wall. What are your thoughts of the future there, and how
are you doing surveillance on these patients?
Dr Dagenais. What I think this study shows is that at least at
midterm and until we have further data on the long-term durability
of these different conduits, the ease of reoperation has to be taken
into account, and doing a reoperation in a calcified root or with the
root Freestyle is much more difficult than doing a redo stented
xenograft. I think that is one of the take-home messages of this
study.
Dr Jamieson. There has been a lot written on bicuspid aortic
valves and valvular pathology in the pulmonary valve and the
pulmonary root and the concept of annular dilatation, and our
Canadian colleague, Dr Tirone David, has written extensively on
that topic as well. I do not believe you have identified any of those
problems here, but can you tell us any of your observations or
concerns?
Dr Dagenais. With annular dilatation with our experience in
the Ross group, we tried to avoid doing Ross procedures in those
patients. In this study we had no reoperation for the pulmonary
homograft because we used the biggest available pulmonary ho-
mograft on the shelf. We have learned this through our early
experiences in younger patients, and I think that is also supported
in the literature.
Dr Jamieson. The concept of patient-prosthesis mismatch, as
popularized by your cardiologist colleagues, is designated with
indexed effective orifice area less than 0.85 cm2/m2. You identified
that there is some element of mismatch in your stented prosthesis
and even your stentless prosthesis. We have identified, along with
your center, that in elderly persons some degree of mismatch does
not influence mass reduction and does not influence survival. Do
you think in this particular age group of more active people with
aerobic activity that some element of mismatch might be impor-
tant? If that is the case, the Ross procedure is a very important
procedure to perform over the other stented or even stentless
procedures.
Dr Dagenais. Well, I think as we showed in this study, func-
tional class was not influenced by valve performance. However, I
think one has to realize also that the mismatch in this cohort,
1048 The Journal of Thoracic and Cardiovascular Surgery ● Maespecially in the stented xenograft and the Freestyle groups, was
about 30%. Most of the mismatches were between 0.75 and 0.85.
Thus I think with mild mismatch, we will not see any effect on
survival or functional class. However, I think if you go under 0.75,
then I think we have to really watch out in this young subgroup not
to have problems with mismatch.
Dr Jamieson. Just 2 other questions. In your final surveillance,
your surveillance of the heterografts, you have used 2 valves. Both
have different failure modes. The Mosaic, if it is going to fail
(some calcification, tear), the patient becomes symptomatic from
insufficiency. The Perimount predominantly fails 85% by calcifi-
cation, and these patients experience insipient stenosis. What is
your surveillance pattern or what are you doing to observe these
because you are putting these heterografts in a population in which
they can be subjected to early degeneration?
Dr Dagenais. All these patients are followed initially with a
clinical visit every year and an echocardiogram every 2 years if
everything is stable, and therefore they are followed pretty closely,
and I think one should have such a follow-up in these patients to
be able to have a good long-term follow-up.
Dr Edward Verrier (Seattle, Wash). I have a couple of brief
questions. The striking data in this are first that the freedom from
reoperation is lowest in the Ross procedure. As we know from the
data in the Ross registry, that procedure reached its heyday in the
mid-1990s and has certainly steadily decreased in use, both be-
cause of the high operative mortality that approaches 4% and the
need for reoperation that approaches 10% over 8 years for the
pulmonary homograft. Do your data include all reoperations on the
pulmonary homograft or just the autograft?
Dr Dagenais. As I discussed, pretty surprisingly in this cohort
of patients, no patients required reoperation for their pulmonary
homograft. We have had that in our younger patients but not in this
cohort of patients, possibly because we started to do the Ross
procedure in a younger age group, and now we know that we have
to use the largest pulmonary homograft conduit available.
Dr Verrier. That certainly would go against what a lot of other
persons reported. The second interesting issue is the reduced
7-year survival benefits with the Freestyle group at 71% and the
stented group at 87% compared with the homograft or Ross
groups. First, this would certainly go against the Toronto experi-
ence, which stated a significant survival benefit with the stentless
valve versus the stented valve technology. Is this a selection bias
or an age bias, or from your data, even though the numbers are
low, do you think that you refute this intermediate survival benefit
with the stentless technology?
Dr Dagenais. Well, I think one has to look into the limitations
of the study. I think age is a very important factor, and I think that
is why we took the cardiac survival because we had 32 deaths
during the follow-up period, 18 of which were of noncardiac cause
and 14 of which were in the Freestyle group. Therefore I think
when you take out those noncardiac deaths with the limitation of
the study, you find that there is no difference between survival
among groups. Now does this go against the Toronto series in
terms of increasing midterm survival? We will have to address this
issue with a longer follow-up. I personally think that with the
current data on stentless valves, it is difficult yet to find a survival
advantage over stented xenograft valves.
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tion that occurs cannot be understated because certainly most of us
have abandoned the homograft except in endocarditis because
when you have to reoperate on a calcified root in a young person,
it is one of the most daunting operations we perform.
Dr Dagenais. I totally agree.
Dr D. Craig Miller (Stanford, Calif). Francois, nice presenta-
tion, but I cannot let you get away with censoring all these
“noncardiac deaths.” I know you did not have autopsies, or did
you? How do you know that those 18 deaths, a lot of which were
probably sudden and unexplained, were not of a cardiac cause?The Journal of Thoracicconservatively approach it is to consider them all, knowing that
you are probably overestimating the incidence of cardiac death, but
at least you are not letting something that smells bad creep into
your data. What would those curves look like with all deaths?
Dr Dagenais. We are the only center to which 3 million
persons are referred, and we have 2 nurses who are truly dedicated
to follow these patients. Most of these patients have autopsies
when they die. I think in such circumstances it is difficult to keep
the noncardiac deaths in the analysis considering the age differ-
ence between the groups. This is, however, a study limitation.
When you include the noncardiac deaths, there was a trend towardA
CDThat has been a bugaboo in any valve series, and the only way to lower survival in the Freestyle and the stented xenograft groups.and Cardiovascular Surgery ● Volume 129, Number 5 1049
